Hugh M. Davis - Dec 2, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and COO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Dec 2, 2024
Transactions value $
$0
Form type
4
Date filed
12/3/2024, 05:42 PM
Previous filing
Nov 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +375K $0.00 375K Dec 2, 2024 Common Stock 375K $3.96 Direct F1, F2
transaction ACRS Restricted Stock Units Award $0 +107K $0.00 107K Dec 2, 2024 Common Stock 107K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the "Plan") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4).
F2 Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service (as defined in the Plan) through each such date.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F4 Four year vesting with 25% of the shares subject to the restricted stock units vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service through each such date.